PUBLICATION

Anxiolytic-like effects of noribogaine in zebrafish

Authors
Kalueff, A.V., Kaluyueva, A., Mailet, E.L.
ID
ZDB-PUB-170510-13
Date
2017
Source
Behavioural brain research   330: 63-67 (Journal)
Registered Authors
Kalueff, Allan V.
Keywords
anxiety, drug abuse, noribogaine, zebrafish
MeSH Terms
  • Animals
  • Anti-Anxiety Agents/metabolism
  • Anti-Anxiety Agents/pharmacology
  • Anxiety/drug therapy
  • Anxiety Disorders/drug therapy
  • Behavior, Animal/drug effects
  • Disease Models, Animal
  • Female
  • Hallucinogens/pharmacology
  • Ibogaine/analogs & derivatives*
  • Ibogaine/metabolism
  • Ibogaine/pharmacology
  • Locomotion/drug effects
  • Male
  • Stress, Physiological/drug effects*
  • Zebrafish/metabolism
  • Zebrafish/physiology
PubMed
28479267 Full text @ Behav. Brain Res.
Abstract
Noribogaine is the main psychoactive metabolite of the hallucinogenic drug ibogaine, and is a particularly interesting compound potentially useful to treat dependence and various psychiatric disorders. Here, we report the effects of noribogaine on anxiety and locomotion in zebrafish (Danio rerio), a new promising model organism in neurobehavioral and psychopharmacological research. Adult zebrafish were subjected to the 5min novel tank test (NTT) following an acute, 20min drug immersion in 1, 5 and 10mg/L noribogaine. Overall, noribogaine produced robust anxiolytic-like behavior in zebrafish (increasing the time spent and transition to the top half compartment and reducing freezing bouts) without overt effects on fish locomotion. Taken together, these results indicate that noribogaine modulates the components of the acute stress response related to emotionality and anxiety behaviors, implicating this drug as a potentially useful non-sedative anxiolytic agent.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping